JP2005519636A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005519636A5 JP2005519636A5 JP2004503917A JP2004503917A JP2005519636A5 JP 2005519636 A5 JP2005519636 A5 JP 2005519636A5 JP 2004503917 A JP2004503917 A JP 2004503917A JP 2004503917 A JP2004503917 A JP 2004503917A JP 2005519636 A5 JP2005519636 A5 JP 2005519636A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- posh
- ubiquitin
- polypeptide
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101000837060 Homo sapiens E3 ubiquitin-protein ligase SH3RF1 Proteins 0.000 description 21
- 102100028660 E3 ubiquitin-protein ligase SH3RF1 Human genes 0.000 description 18
- 229920001184 polypeptide Polymers 0.000 description 18
- 102000004196 processed proteins & peptides Human genes 0.000 description 18
- 108090000765 processed proteins & peptides Proteins 0.000 description 18
- 239000000126 substance Substances 0.000 description 11
- 150000007523 nucleic acids Chemical class 0.000 description 10
- 102000044159 Ubiquitin Human genes 0.000 description 9
- 108090000848 Ubiquitin Proteins 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 239000012634 fragment Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000034512 ubiquitination Effects 0.000 description 5
- 238000010798 ubiquitination Methods 0.000 description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 108020004459 Small interfering RNA Proteins 0.000 description 4
- 101800001117 Ubiquitin-related Proteins 0.000 description 4
- 108091030071 RNAI Proteins 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000009368 gene silencing by RNA Effects 0.000 description 3
- 102000052665 human SH3RF1 Human genes 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000029302 virus maturation Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34584601P | 2001-11-09 | 2001-11-09 | |
| US36453002P | 2002-03-15 | 2002-03-15 | |
| PCT/US2002/036366 WO2003095971A2 (en) | 2001-11-09 | 2002-11-12 | Posh nucleic acids, polypeptides and related methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005519636A JP2005519636A (ja) | 2005-07-07 |
| JP2005519636A5 true JP2005519636A5 (enExample) | 2006-01-05 |
Family
ID=26994569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004503917A Pending JP2005519636A (ja) | 2001-11-09 | 2002-11-12 | Ｐｏｓｈ核酸、ポリペプチド及び関連する方法、関連する用途 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US7250250B2 (enExample) |
| EP (1) | EP1310552B1 (enExample) |
| JP (1) | JP2005519636A (enExample) |
| AT (1) | ATE364690T1 (enExample) |
| AU (1) | AU2002365160C1 (enExample) |
| CA (1) | CA2465973C (enExample) |
| DE (1) | DE60220621T2 (enExample) |
| IL (2) | IL161764A0 (enExample) |
| NZ (1) | NZ532908A (enExample) |
| WO (1) | WO2003095971A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602004025708D1 (de) | 2003-07-11 | 2010-04-08 | Proteologics Inc | Ubiquitin-ligase-hemmer und verwandte verfahren |
| US20060188890A1 (en) * | 2003-10-31 | 2006-08-24 | Proteologics, Inc. | Ubiquitin-based protein interaction assays and related compositions |
| JP2008517278A (ja) * | 2004-10-15 | 2008-05-22 | シグナル ファーマシューティカルズ，エルエルシー | ｐ２７のユビキチン化アッセイ及びその使用方法 |
| EP2482075A1 (en) | 2004-12-01 | 2012-08-01 | Proteologics, Ltd | Ubiquitin ligase assays and related reagents |
| JP2008092911A (ja) * | 2006-10-16 | 2008-04-24 | Univ Of Tokyo | タンパク質結合検出方法 |
| EP2196794A4 (en) * | 2007-08-30 | 2014-04-02 | Mitsui Shipbuilding Eng | DEVICE AND METHOD FOR DETECTING FLUORESCENCE ENERGY TRANSFER (FRET) |
| WO2010039543A2 (en) | 2008-09-23 | 2010-04-08 | Traversa Therapeutics, Inc. | Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference |
| US9901617B2 (en) * | 2013-08-14 | 2018-02-27 | The Curators Of The University Of Missouri | Cell permeable inhibitors of the scaffold protein plenty of SH3 domains (POSH) or Sh3Rfl |
| WO2018085208A1 (en) | 2016-11-02 | 2018-05-11 | The Research Foundation For The State University Of New York | Methods of inhibiting viruses using compositions targeting tsg101-ubiquitin interaction |
| CN106754883B (zh) * | 2016-12-30 | 2019-10-29 | 中山大学 | 一种一步、无缝、非同源、多片段的基因拼接改造方法及其试剂盒 |
| CN112764372A (zh) * | 2020-12-25 | 2021-05-07 | 天津大学 | 基于vpx架构的多通道信号采集系统 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000008181A2 (en) * | 1998-08-07 | 2000-02-17 | Onyx Pharmaceuticals, Inc. | Chp polypeptide, a ligand of pak65 |
| WO2000022142A2 (en) * | 1998-10-13 | 2000-04-20 | Onyx Pharmaceuticals, Inc. | Cell signaling polypeptides and nucleic acids |
| WO2000027865A1 (en) | 1998-11-06 | 2000-05-18 | The Brigham And Women's Hospital, Inc. | CHARACTERIZATION OF NOVEL GENE cbl-SL |
| US7432049B2 (en) | 2001-02-28 | 2008-10-07 | Chondrogene Limited | Compositions and methods relating to osteoarthritis |
| EP1074617A3 (en) | 1999-07-29 | 2004-04-21 | Research Association for Biotechnology | Primers for synthesising full-length cDNA and their use |
| WO2001018542A2 (en) | 1999-09-03 | 2001-03-15 | Millennium Pharmaceuticals, Inc. | Identification, assessment, prevention, and therapy of ovarian cancer |
| WO2001055448A1 (en) | 2000-01-31 | 2001-08-02 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
| AU2001234944A1 (en) | 2000-02-03 | 2001-08-14 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| AU2001241541A1 (en) | 2000-02-17 | 2001-08-27 | Millennium Predictive Medicine, Inc. | Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer |
| AU2001238347A1 (en) | 2000-02-28 | 2001-09-12 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| AU4592601A (en) | 2000-03-21 | 2001-10-03 | Millennium Predictive Medicine | Novel genes, compositions, kits, and method for identification, assessment, prevention, and therapy of ovarian cancer |
| WO2001071042A2 (en) | 2000-03-23 | 2001-09-27 | Pe Corporation (Ny) | Detection kits, such as nucleic acid arrays, for detecting the expression of 10,000 or more drosophila genes and uses thereof |
| US20020045170A1 (en) | 2000-04-06 | 2002-04-18 | Wong Gordon G. | Polynucleotides encoding novel secreted proteins |
| AU2001263006A1 (en) | 2000-05-18 | 2001-11-26 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| US7105293B2 (en) | 2000-09-19 | 2006-09-12 | Whitehead Institute For Biomedical Research | Genetic markers for tumors |
| CA2426540A1 (en) | 2000-10-20 | 2002-07-25 | Biocardia, Inc. | Leukocyte expression profiling |
| EP1629082A4 (en) | 2000-10-20 | 2009-07-22 | Univ Massachusetts | GENERIC CONNECTIONS AND THEIR USES OF GLUCOSE TRANSPORT |
| WO2003008647A2 (en) | 2000-11-28 | 2003-01-30 | University Of Cincinnati | Blood assessment of injury |
| WO2002077235A2 (en) | 2000-12-21 | 2002-10-03 | Incyte Genomics, Inc. | Intracellular signaling molecules |
| WO2002053719A2 (en) * | 2001-01-04 | 2002-07-11 | Incyte Genomics, Inc. | Cytoskeleton-associated proteins |
| EP1425302A2 (en) | 2001-01-24 | 2004-06-09 | Protein Design Labs | Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer |
| US6743619B1 (en) | 2001-01-30 | 2004-06-01 | Nuvelo | Nucleic acids and polypeptides |
| EP1383894A2 (en) * | 2001-03-28 | 2004-01-28 | Incyte Genomics, Inc. | Molecules for disease detection and treatment |
| US20040236091A1 (en) | 2001-03-28 | 2004-11-25 | Chicz Roman M. | Translational profiling |
| WO2002085285A2 (en) | 2001-04-18 | 2002-10-31 | Wyeth | Methods and reagents for regulating bone and cartilage formation |
| CA2447357A1 (en) | 2001-05-22 | 2002-11-28 | Gene Logic, Inc. | Molecular toxicology modeling |
| WO2003022987A2 (en) | 2001-07-26 | 2003-03-20 | Eos Biotechnology, Inc. | Methods of diagnosis of hepatitis c infection, compositions and methods of screening for modulators of hepatitis c infection |
| CA2455899A1 (en) | 2001-07-31 | 2003-04-24 | Yuval Reiss | Compositions and methods for the modulation of viral maturation |
| CA2459219A1 (en) | 2001-09-17 | 2003-03-27 | Protein Design Labs, Inc. | Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer |
| CA2460283A1 (en) | 2001-10-31 | 2003-05-08 | Pfizer Products Inc. | Therapeutics and diagnostics for disorders of erythropoiesis |
| US20030175253A1 (en) | 2001-11-09 | 2003-09-18 | Huda Akil | Compositions and methods for diagnosing and treating mental disorders |
| US20040096828A1 (en) * | 2002-01-04 | 2004-05-20 | Lu Dyung Aina M | Cytoskeleton-associated proteins |
-
2002
- 2002-11-11 DE DE60220621T patent/DE60220621T2/de not_active Expired - Lifetime
- 2002-11-11 EP EP02257796A patent/EP1310552B1/en not_active Expired - Lifetime
- 2002-11-11 AT AT02257796T patent/ATE364690T1/de not_active IP Right Cessation
- 2002-11-12 AU AU2002365160A patent/AU2002365160C1/en not_active Ceased
- 2002-11-12 IL IL16176402A patent/IL161764A0/xx unknown
- 2002-11-12 CA CA2465973A patent/CA2465973C/en not_active Expired - Fee Related
- 2002-11-12 JP JP2004503917A patent/JP2005519636A/ja active Pending
- 2002-11-12 US US10/293,965 patent/US7250250B2/en not_active Expired - Fee Related
- 2002-11-12 NZ NZ532908A patent/NZ532908A/en not_active IP Right Cessation
- 2002-11-12 WO PCT/US2002/036366 patent/WO2003095971A2/en not_active Ceased
-
2004
- 2004-05-04 IL IL161764A patent/IL161764A/en not_active IP Right Cessation
-
2005
- 2005-01-06 US US11/031,482 patent/US7429643B2/en not_active Expired - Fee Related
- 2005-01-07 US US11/031,737 patent/US7268227B2/en not_active Expired - Fee Related
-
2007
- 2007-07-30 US US11/881,958 patent/US20080187538A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7645323B2 (ja) | Ｂ型肝炎感染の治療方法 | |
| JP7357002B2 (ja) | 高コレステロール血症及び関連状態を治療するための、ｐｃｓｋ９を標的とするオリゴヌクレオチド | |
| US8288358B2 (en) | Therapeutic targets and molecules | |
| US6831171B2 (en) | Nucleic acid catalysts with endonuclease activity | |
| US20040009510A1 (en) | Allosteric nucleic acid sensor molecules | |
| US7196184B2 (en) | Double-stranded RNA (DSRNA) and method of use for inhibiting expression of the AML-1/MTG8 fusion gene | |
| JPH08506479A (ja) | Ｃ型肝炎ウイルス関連疾患の治療のための組成物および方法 | |
| KR20230170732A (ko) | 케토헥소키나제 (khk)를 억제하기 위한 조성물 및 방법 | |
| JP2014533953A (ja) | 治療用ｒｎａスイッチ組成物及び使用方法 | |
| JP2021511042A (ja) | Ａｌｄｈ２発現を阻害するための組成物及び方法 | |
| US12534730B2 (en) | Compositions and methods for inhibiting GYS2 expression | |
| JP2022514501A5 (enExample) | ||
| US20020102568A1 (en) | Nucleic acid sensor molecules | |
| WO2020139764A1 (en) | Compositions and methods for inhibiting hmgb1 expression | |
| Scaggiante et al. | Effect of unmodified triple helix‐forming oligodeoxyribonucleotide targeted to human multidrug‐resistance gene mdr1 in MDR cancer cells | |
| US8008471B2 (en) | Nucleic acids for inhibiting hairless protein expression and methods of use thereof | |
| EP1591524A1 (en) | Oligoribonucleotide or peptidic nucleic acid inhibiting function of hepatitis c virus | |
| JP2007523658A (ja) | アレルギー性疾患を治療するための物質および方法 | |
| US20040072783A1 (en) | Nucleozymes with endonuclease activity | |
| WO2003089650A2 (en) | Allosteric nucleic acid sensor molecules | |
| US20030065155A1 (en) | Nucleic acid sensor molecules | |
| KR100848665B1 (ko) | 서바이빈의 발현을 억제하는 ｓｉＲＮＡ | |
| JP2002512791A (ja) | Ｃ型肝炎ウイルス感染に関連する疾患または状態の酵素的核酸治療 | |
| CA2397813A1 (en) | Method and reagent for the inhibition of grid | |
| CN120092089A (zh) | 抗病毒核酸和组合物 |